The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome
Abstract
OBJECTIVE: To evaluate the efficacy and safety of topiramate as adjunctive therapy for Lennox-Gastaut syndrome in a multicenter, double-blind, placebo-controlled trial. BACKGROUND: Conventional antiepileptic drugs are frequently ineffective against multiple-seizure types of Lennox-Gastaut syndrome. METHODS: Ninety-eight patients >1 year to <30 years of age, with slow spike-and-wave patterns on EEG, seizure types including drop attacks, and either a history of or active atypical absence seizures, were assigned to an 11-week, double-blind treatment phase with either topiramate or placebo. Topiramate was titrated to target doses of approximately 6 mg/kg/d. RESULTS: For drop attacks, the most severe seizures associated with this syndrome, the median percentage reduction from baseline in average monthly seizure rate was 14.8% for the topiramate group and -5.1% (an increase) for the placebo group (p = 0.041). Topiramate-treated patients demonstrated greater improvement in seizure severity than did placebo-treated patients based on parental global evaluations (p = 0.037). The percentage of patients with a > or = 50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was greater in the topiramate group (15/46 or 33%) than in the control group (4/50 or 8%; p = 0.002). The most common adverse events in both groups were CNS related; there were no discontinuations from topiramate therapy due to adverse events. CONCLUSIONS: Topiramate adjunctive therapy was effective in reducing the number of drop attacks and major motor seizures and in improving seizure severity as determined by parental global evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Guerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Self-citationChiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568
Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome
Glauser, T., Kluger, G., Sachdeo, R., Krauss, G., Perdomo, C., & Arroyo, S. (2008) · Neurology · doi:10.1212/01.wnl.0000303813.95800.0d · Cited by 356
Self-citationTreatment of pediatric epilepsy: European expert opinion, 2007
Wheless, J. W., Clarke, D. F., Arzimanoglou, A., & Carpenter, D. (2007) · Epileptic Disorders · doi:10.1684/epd.2007.0144 · Cited by 295
Metadata
- Authors
- Sachdeo, R. C., Glauser, T. A., Ritter, F., Reife, R., Lim, P., Pledger, G., & the Topiramate YL Study Group
- Venue
- Neurology
- Published
- 1999-06
- Volume
- 52
- Issue
- 9
- Pages
- 1882-1882
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2093392404
- Cited by
- 380
- References
- 1
- FWCI
- 17.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. https://app.cochat.ai/papers/10.1212/wnl.52.9.1882
- The paper
- Sachdeo, R. C., Glauser, T. A., Ritter, F., Reife, R., Lim, P., Pledger, G., & the Topiramate YL Study Group. (1999). A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology. https://doi.org/10.1212/wnl.52.9.1882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.